MacroGenics Inc (MGNX)

NASDAQ
17.33
+0.72(+4.33%)
After Hours
17.33
0.00(0.00%)
- Real-time Data
  • Volume:
    450,230
  • Bid/Ask:
    16.50/18.34
  • Day's Range:
    16.43 - 17.80

MGNX Overview

Prev. Close
16.61
Day's Range
16.43-17.8
Revenue
115.99M
Open
16.64
52 wk Range
16.43-36.48
EPS
-2.46
Volume
450,230
Market Cap
1.06B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
673,254
P/E Ratio
-
Beta
2.07
1-Year Change
-22.25%
Shares Outstanding
61,258,001
Next Earnings Date
01 Mar 2022
What is your sentiment on MacroGenics Inc?
or
Market is currently closed. Voting is open during market hours.

MacroGenics Inc Company Profile

Employees
370

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company’s approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company’s non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsBuyStrong BuyBuyStrong SellStrong Sell
SummaryBuyBuyNeutralStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.